The course of adverse effects of nortriptyline and venlafaxine during 3-year treatment in elderly patients with major depression by Kok, R. et al.
VU Research Portal
The course of adverse effects of nortriptyline and venlafaxine during 3-year treatment
in elderly patients with major depression
Kok, R.; Aartsen, M.J.; Nolen, A.; Heeren, T.J.
published in
Journal of the American Geriatrics Society
2009
DOI (link to publisher)
10.1111/j.1532-5415.2009.02524.x
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Kok, R., Aartsen, M. J., Nolen, A., & Heeren, T. J. (2009). The course of adverse effects of nortriptyline and
venlafaxine during 3-year treatment in elderly patients with major depression. Journal of the American Geriatrics
Society, 57(11), 2112-2117. https://doi.org/10.1111/j.1532-5415.2009.02524.x
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 22. Apr. 2021
The Course of Adverse Effects of Nortriptyline and Venlafaxine in
Elderly Patients with Major Depression
Rob M. Kok, PhD, Marja Aartsen, PhD,w Willem A. Nolen, PhD,z and Thea J. Heeren, PhD§
OBJECTIVES: To evaluate tolerability and course of ad-
verse effects of antidepressants in elderly patients and to
study the association between number and severity of ad-
verse effects and age, physical comorbidity, antidepressant
dose. and depression severity.
DESIGN: Double-blind, randomized controlled trial fol-
lowed by an open treatment phase of 3 years.
SETTING: Psychiatric hospital in the Netherlands.
PARTICIPANTS: Eighty-one elderly depressed inpatients.
INTERVENTION: Patients were treated with venlafaxine
or nortriptyline.
MEASUREMENTS: Frequency and severity of 43 individ-
ual adverse effects were assessed using the Symptom, Sign,
Side-Effect Checklist. Severity of depression was assessed
using the Montgomery Åsberg Depression Rating Scale.
RESULTS: Both antidepressants were tolerated well, with
no differences in clinical effectiveness, and most adverse
effects decreased with time. The number and severity of
adverse effects was not related to age or physical comor-
bidities. There was a significant relationship between the
severity of depression and the severity of adverse effects,
although the relationship between the dose of the antide-
pressant and the severity of the adverse effects was of only
borderline statistical significance.
CONCLUSION: Elderly patients tolerated venlafaxine
and nortriptyline well, and most adverse effects decreased
with time as the depression improved. Age and physical
comorbidities were not related to number and severity of
adverse effects. J Am Geriatr Soc 57:2112–2117, 2009.
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randomized controlled trial
The short-term efficacy and safety of antidepressants inelderly people have been established in many random-
ized controlled trials (RCTs), reviews, and meta-analyses,1–4
but many elderly patients with depression do not receive
adequate treatment with antidepressants. A recent retro-
spective study of 12,130 new antidepressant users aged 65
and older found that 34.8% of these patients were taking
suboptimal doses of antidepressants.5 Fear of adverse effects
when using higher doses may be an important reason for
using such suboptimal treatment regimes. Elderly patients
with depression are particularly prone to adverse effects as a
result of age-associated changes in pharmacokinetics and
pharmacodynamics, drug interactions, and the presence of
comorbid physical disorders. In a recent meta-analysis of 37
RCTs comparing tricyclic antidepressants (TCAs) and se-
lective serotonin reuptake inhibitors (SSRIs) in elderly peo-
ple, it was recognized that recipients of TCAs had not only
had a greater withdrawal rate but that this was also specifi-
cally due to adverse effects.6
The authors feel that more patients might be willing to
continue their treatment with antidepressants if practitioners
were able to inform patients about the prognosis of adverse
effects over time. Therefore, it is important to be able to
predict the likely course of (specific) adverse effects and
to have knowledge about the influence of dose increase on the
severity of adverse effects. Only two studies7,8 have addressed
the longitudinal outcome and course of adverse effects in
younger adult patients and only three such studies9–11 in
elderly patients. All of these studies found that adverse effects
decreased in frequency over time and that total adverse
effect scores were related primarily to residual depression
rather than to treatment with antidepressants. None of these
studies addressed the influence of age, physical comorbidity,
or antidepressant dose on adverse effects. To the best of
the authors’ knowledge, no double-blind study in elderly
people has addressed the course of adverse effects during the
acute treatment of depression.
A randomized, double-blind trial lasting 12 weeks
compared the effect of nortriptyline and venlafaxine in el-
derly depressed patients.12 All patients were asked to par-
ticipate in an open-treatment phase for a maximum of 3
years. The questions addressed were: Is there a difference in
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tolerability of both antidepressants? What is the course of
adverse effects? and What is the relationship between the
number and severity of adverse effects and age, physical
comorbidity, antidepressant dose, and depression severity.
The hypothesis was that venlafaxine would be better
tolerated than nortriptyline and that only a few adverse
effects would persist during continued treatment. The hy-
pothesis was also that the number and severity of adverse




A double-blind, randomized 12-week parallel-group trial
was conducted in inpatients aged 60 and older with de-
pression. Patients were enrolled if they met Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for major depression (single or recurrent
episode) and had a score of at least 20 on the Montgomery-
Åsberg Depression Rating Scale (MADRS; normal range
0–9).13 Patients were excluded if they met DSM-IV criteria
for dementia or had a Mini-Mental State Examination
(MMSE; normal range 24–30)14 score of less than 15, if
there was an absolute contraindication to the study med-
ication (e.g., a recent myocardial infarction), or if they had
already been treated unsuccessfully for the present episode
with venlafaxine (4 weeks, 75 mg) or with a TCA in-
cluding nortriptyline (4 weeks, serum level within thera-
peutic range).
Details about the flexible dosing schedule of ve-
nlafaxine and nortriptyline, the use of adjunctive medica-
tion, and the efficacy results have been published
elsewhere.12 Written informed consent was obtained from
all patients, or in case of lack of capacity to consent to the
trial, consent was obtained from their legal representative.
The ethics committee of the Altrecht Institute of Mental
Heath Care (Zeist, the Netherlands) approved the trial,
which was conducted according to the Declaration of
Helsinki.
After the initial, double-blind phase, patients were
asked to participate in an open study with a follow-up
duration of 3 years. Decisions in the open-treatment
phase about stopping the antidepressant in case of severe
adverse effects or if a patient was in sustained remission
were made at the attending physician’s discretion.
Study Assessment
During the double-blind phase, patients were assessed at
Weeks 1, 3, 5, 7, 9, and 12. During the open-treatment
phase, assessments were done at 6, 9, 12, 24, and 36 months
after the start of the double-blind phase.
Antidepressant safety was assessed at all visits with the
Symptom, Sign, Side-Effect Checklist (SES)15 evaluating
the presence and severity (rated as 1 5 mild, 2 5 moderate,
3 5 severe) of 43 symptoms or adverse effects. Any symp-
tom present at baseline that had not increased in severity
since start of the study medication was not rated as an ad-
verse effect. After each visit, the global burden of adverse
effects was calculated by summing the SES severity scores of
all individual adverse effects.
The primary tolerability outcome criterion was the
percentage of patients dropping out as a result of adverse
events during the double-blind treatment phase. Taking into
consideration a 22.9% rate of drop out in the nortriptyline
group, as found in patients using a TCA according to a
recent review,6 and using an alpha of 0.05 and a power of
0.8, 247 patients would have to be included in each group
to find a difference between nortriptyline and venlafaxine of
10% in the proportion of patients dropping out.
The first author made all safety assessments. Severity of
depression was evaluated at all visits using the MADRS.
Severity and disability resulting from physical illnesses were
recorded according to a previously developed method.16
Statistical Analysis
Cross-sectional analysis of the progression of the number
and severity of adverse effects during the 3 years of
treatment were analyzed using conventional statistical
techniques (Student t-test, chi-square (w2), Pearson correla-
tion). In addition, longitudinal data analyses were per-
formed using latent growth models (LGMs).17,18 A LGM is
a specific type of structural equation model that gives an
adequate description of the amount of change observed be-
cause it takes into account the lack of reliability of the
measurements and the nonlinearity of the trajectories of
change.19 In this study, a LGM was used to explicitly test
the nonlinear course of adverse events by comparing the
goodness-of-fit statistics (the comparative fit index (CFI)
and the root mean square error of approximation
(RMSEA)) of two nested models. Cross-domain LGM is
an extension of the LGM in the sense that, next to a
description in the course of adverse effects, relationships
between patterns of change on different variables can also
be estimated.
The conventional analyses were conducted using SPSS
14.0 for Windows (SPSS, Inc., Chicago, IL) using two-sided
tests, and test statistics are presented with P-values. To
correct for multiple testing, P.01 was considered signifi-
cant for all post hoc analyses and P 5.05 to .01 was con-
sidered of borderline significance. The analyses on the
longitudinal data (LGM) were performed using Mplus
(Muthén & Muthén, Los Angeles, CA).
RESULTS
The sample consisted of 81 patients who started the double-
blind RCT. Baseline demographic and clinical variables are
presented in Table 1. The results of the double-blind treat-
ment phase are first presented; only limited data on the 3
years of follow-up are presented, because it was desired not
to mix results from a double-blind treatment phase with a
predetermined dosing schedule with results from the 3 years
of nonblind observations in which doses could be changed
according to the psychiatrists’ discretion. In addition, the
majority of patients stopped their antidepressant during the
3 years of open treatment, limiting the power of statistical
analysis.
The mean dose and standard deviation at the end of the
RCT in patients using venlafaxine was 156  71 mg/d; the
mean dose of nortriptyline was 94.5  30.4 mg/d.
The first research question concerned a possible differ-
ence in tolerability between both antidepressants. Three
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patients treated with nortriptyline and two treated with
venlafaxine stopped it because of adverse effects. The only
adverse effect with statistical significance in prevalence
was dry mouth, which was more prevalent in patients
taking nortriptyline (87.8%, vs 50% of patients taking
venlafaxine; w2 5 13.6, degrees of freedom (df) 5 1,
Po.001).
Table 2 presents the number of at least moderately se-
vere adverse effects per patient at each visit. Table 3
presents the severity of the adverse effects at each visit. No
statistically significant difference in adverse effects between
the two drugs could be demonstrated at any visit. Because it
was more likely that patients with more-severe adverse
effects would drop out of the trial, the analyses in Tables 2
and 3 were repeated with a completer’s analysis and with a
last observation carried forward technique, which yielded
the same results.
The second research question concerned the course of
adverse events. Table 2 suggest an initial increase followed
by a decrease in the number of side effects in both patient
groups. The LGM confirmed this nonlinear pattern. The fit
of the model in which nonlinear change was modeled was
excellent (w2 5 10.60, df 5 12, P 5.39, CFI 5 1.00,
RMSEA 5 0.03), which is significantly better than the fit
of the model with linear change (w2 5 20.00, df 5 12,
P 5.07, CFI 5 0.96, RMSEA 5 0.09).
The third research question concerned the relationship
between the number and severity of adverse effects and
several potential determinants.
Age
There was no statistically significant relationship between
age and number or severity of adverse effects.
Physical Illness
No significant correlation could be demonstrated between
the number or severity of the physical illnesses and the
number or severity of adverse effects (correlation coefficient
(r) 5 0.00–0.25, all except one P-value 4.05).
Dose
The mean daily dose of venlafaxine increased from 75 mg at
Week 1 to a maximum of 162  69 mg at Week 9, and the
dose of nortriptyline increased from 75 mg at Week 1 to a
maximum of 131  63 at Week 9. There was no statistically
significant cross-sectional correlation between dose and
number of adverse effects (Pearson r 5 0.07–0.22; all P-
values 4.05), although the cross-sectional correlation be-
tween dose of antidepressant and severity of adverse effects
was of borderline significance (r 5 0.29–0.38, all P-values
o.05 and one P-value o.01).
Depression Severity
The cross-sectional correlation between MADRS score and
number of adverse effects was of borderline significance in
all except the first visit after start of the medication
(r 5 0.25–0.36, with all P-values o.05 and only one
P-value o.01). To detect whether changes in MADRS





(n 5 41) P-Value
Age, mean  SD 71.6  6.8 72.8  8.4 .48
Female, n (%) 27 (67.5) 32 (78.1) .29
Duration current episode, months mean  SD 6.2  5.1 4.7  3.4 .20
Montgomery Åsberg Depression Rating Scale score, mean  SD (normal range 0–9) 32.9  6.4 32.9  6.0 4.99
Patients taking concomitant psychiatric medications, n (%) 33 (82.5) 36 (87.8) .50
Number of concomitant psychiatric medications, mean  SD 1.4  0.9 1.7  0.9 .40
Concomitant number of physical illnesses, mean  SD 6.3  2.4 6.3  2.5 .97
Concomitant number of somatic medications, mean  SD 3.0  2.2 3.4  3.0 .68
SD 5 standard deviation.
Table 2. Number of at Least Moderately Severe Adverse








2 1 81 4.0  4.4 3.4  3.0 .48
3 3 79 3.8  3.4 4.2  2.9 .56
4 5 75 4.7  3.9 4.9  3.0 .75
5 7 74 4.5  3.6 5.0  4.2 .63
6 9 68 4.6  4.6 4.5  3.2 .86
7 12 62 2.4  2.7 3.5  3.5 .14
Table 3. Total Severity of Adverse Effects in Elderly








2 1 81 18.3  8.6 16.8  6.8 .38
3 3 79 15.0  8.3 15.4  7.6 .83
4 5 75 16.2  8.7 15.9  7.0 .88
5 7 74 14.3  9.2 13.8  7.7 .80
6 9 68 12.7  8.4 12.9  6.5 .94
7 12 62 13.5  9.5 11.9  6.5 .46
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score were correlated with changes in the number of ad-
verse effects, a cross-domain LGM was applied. The fit of
the model was good (w2 5 60.82, df 5 51, P 5.16,
CFI 5 0.98, RMSEA 5 0.05), and a significant covariation
was found between change in MADRS score and change in
number of adverse effects (covariance 5 0.10, 95% confi-
dence interval 5 0.03–0.17).
MADRS score was also significantly correlated cross-
sectionally with severity of adverse effects (r 5 0.52–
0.71, all P-values o.01). An estimation of the longitu-
dinal correlation between change in MADRS score and
change in severity of side effects failed, partly because of
the absence of a relationship between change of severity
and time.
Follow-Up
During the 3 years of open treatment, three patients stopped
using venlafaxine, and three patients stopped using
nortriptyline because of adverse effects. Their depression
was in remission at the time of dropout. A survival analysis
including the double-blind and the open-treatment phases
could not demonstrate a difference between the antidepres-
sants in dropouts due to side effects (Wald 0.345, df 5 1,
P 5.56).
After 3 years of observation, 22 patients who started
with nortriptyline continued with it, whereas only four of
the patients who started with venlafaxine were still taking
it. This difference in attrition rate is the result of a higher
number of patients stopping venlafaxine because of a lack
of efficacy, not adverse events.
The number and severity of all adverse events decreased
gradually during the follow-up phase in both antidepres-
sants, with no statistically significant difference between
venlafaxine and nortriptyline at any visit. Dry mouth was
the most frequent adverse effect of nortriptyline throughout
the open-treatment phase, with a prevalence of 43% after 3
years (9/22 patients). Other anticholinergic adverse events
persisted in a much smaller minority of patients using nor-
triptyline (constipation in 2 patients and impaired urination
in 1 patient). In patients taking venlafaxine, the most prev-
alent adverse effect in the open-treatment phase was weight
gain (8/16 patients at 6 months and 4/9 patients at
9 months, in later visits the number was too small for
analysis).
DISCUSSION
There are few trials reporting the long-term tolerance of
adverse effects of antidepressants in elderly people, whereas
medication is often taken for longer periods of time. In the
current study, most patients tolerated venlafaxine and nor-
triptyline well in the double-blind phase and the open-
treatment phase. The primary outcome criterion was the
percentage of patients dropping out as a result of adverse
events during the double-blind treatment phase; a statisti-
cally significant difference could not be demonstrated be-
tween venlafaxine and nortriptyline. In addition, after 3
years of open treatment, no difference in tolerability be-
tween nortriptyline (6 dropouts because of adverse effects)
and venlafaxine (5 dropouts because of adverse effects)
could be demonstrated. These results are in concordance
with the good long-term tolerability of nortriptyline as
shown in double-blind RCTs of maintenance treatment
with this TCA in elderly patients with depression in remis-
sion.20,21 Patients who entered the open-treatment phase
were by definition a cohort that had been proven to tolerate
the study drug for at least 12 weeks during the double-blind
phase.
The dropout rate due to adverse effects in the double-
blind phase of the study (6.2%) was significantly lower than
the withdrawal rate of 22.9% due to adverse effects with
TCAs and of 17.3% with SSRIs in patients included in a
recent meta-analysis6 of adverse effects in elderly patients
with depression (P 5.003 and .02, respectively). Perhaps
the frequent and systematic assessment of the presence and
severity of possible adverse effects contributed to the low
dropout rate. In the authors’ experience, most patients
are willing to continue the antidepressant after discussing
the advantages of continuing treatment, the delay in re-
sponse due to a switch to another antidepressant, and the
possibility of supportive countermeasures. Moreover, all of
the patients started as inpatients, and only a small minority
were discharged before a response was achieved, in contrast
to the outpatients in the majority of studies included in the
meta-analysis. Therefore, the surprisingly low dropout rate
may also reflect that the nursing staff encourages patients to
continue treatment in inpatients wards.
The course of adverse effects was the second research
question, and this is the first double-blind study that
presents the course of adverse effects in more detail during
the acute phase of treatment in elderly patients. An inter-
esting and new finding is the initial increase followed by a
decrease in number of adverse effects. An open study in
elderly patients found a decline in frequency of somatic
complaints during 7 consecutive months of treatment with
nortriptyline.9 In the only adult study that the authors are
aware of to compare these results with, an immediate and
constant, although not linear, decline in number of adverse
events in each consecutive visit was found.7 A different
dosing schedule may explain this different course; the pre-
vious study used a fixed dose regimen and the current study
used a flexible dose regimen with an increase in mean dose
during the first weeks of treatment.
After 2 to 3 years of treatment, most patients reported
one to two adverse effects, compared with four to five ad-
verse effects at maximum during the double-blind treat-
ment phase, which confirms the second research hypothesis.
Because only a few patients dropped out because of adverse
events, the early dropout of the patients suffering from
the most-severe adverse events probably does not explain
the results. Dry mouth was the most persistent adverse
effect in this study population, which is in accordance with
a previous report in elderly people.11
This may prove that better explanation to patients of
the fact that adverse events might decrease in number and
severity with time might influence outcome of antidepres-
sant use in this patient group.
The third research question concerned possible deter-
minants of tolerability. To the best of the authors’ knowl-
edge, this study is the first RCT in adult or elderly patients
that has explored the relationship between adverse effects
and age, physical comorbidity, and antidepressant dose.
Age and physical comorbidity were associated neither with
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the number nor with the severity of adverse effects. This is
in keeping with results of another study in elderly patients
with depression, in which no relationship was found be-
tween adverse effects and physical comorbidities.22 This
suggests that age and (age-associated) physical illnesses may
not have as a great influence on tolerability as often
thought.
No relationship was found between the number of ad-
verse effects and the dose of antidepressants. There was a
low correlation, although of borderline statistical signifi-
cance, between the severity of adverse effects and antide-
pressant dose. Because there was only a limited variation in
the prescribed dosages, especially in patients treated with
venlafaxine, these results need replication before more-
definitive conclusions can be drawn. These data can be
compared only with the finding that there was no significant
correlation between the global burden of adverse effects
and the blood levels of nortriptyline in a nonblind study of
elderly patients.9
Depression severity was associated with the number,
although with borderline statistical significance, and sever-
ity of adverse effects. This is in concordance with an earlier
report in elderly patients.10 This is the first study in elderly
people to replicate the moderate but significantly correla-
tion found between decrease in reported adverse events and
decrease in severity of depression in adult patients.7
If confirmed, the lack of association between
adverse effects and antidepressant dose suggests that clini-
cians should be reluctant to reduce antidepressant dose to
improve adverse effects. The significant association be-
tween adverse effects and depression severity is an addi-
tional argument for clinicians to convince patients not to
lower an adequate dose of antidepressant, because a sub-
optimal treatment strategy will result in a lower chance of
remission.
The number of patients in this study may have limited
its power, and according to the power analysis, the possi-
bility of a type II error cannot be excluded, although this
was the case with other similar studies too. Nevertheless,
there was an increasing imbalance between the number of
patients using nortriptyline and venlafaxine during the
open-treatment phase, although this was due to differences
in efficacy and not in tolerability. Another limitation is the
use of nortriptyline and venlafaxine, neither of which is a
first-line antidepressant for use in elderly people. Both an-
tidepressants were chosen because it was anticipated that
the subjects, being inpatients, would suffer from more-se-
vere depression, often with psychotic features. The Expert
Consensus Guideline on pharmacotherapy of depressive
disorders in older patients suggests that both antidepres-
sants are adequate treatment strategies in these subgroups
of patients with depression.23
CONCLUSION
These data support the long-term tolerability of nortripty-
line and venlafaxine in elderly patients who need mainte-
nance treatment and suggest that adverse events diminish in
frequency in most of these patients. Nevertheless, it remains
difficult to determine the origin of somatic complaints dur-
ing treatment with antidepressants.
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